SUPN Q1 2025 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

Q1 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$150M+4.3% YoY

Gross Profit

$134M89.5% margin

Operating Income

-$10M-6.8% margin

Net Income

-$12M-7.9% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

-14.0%

Cash Flow

Operating Cash Flow

$31M

Free Cash Flow

$30M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$317M

Stockholders' Equity

$1.0B

Cash & Equivalents

$116M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$150M	$144M	+4.3%
Gross Profit	$134M	$127M	+5.3%
Operating Income	-$10M	-$3M	-225.3%
Net Income	-$12M	$124,000	-9637.9%

Revenue Segments

Product

$142M49%

Qelbree

$65M22%

GOCOVRI

$31M11%

APOKYN

$15M5%

Trokendi Xr

$13M4%

Oxtellar X R

$10M3%

Manufactured Product, Other

$9M3%

Royalty, License And Other Revenue

$8M3%